VYGR · Voyager Therapeutics, Inc. · Executive Compensation
$1.73
-0.02 (-1.14%)
At close · Oct 27
Return incl. dividend (before tax)
Q4 2024 earnings call transcript
Market Cap
$107.83M
Shares
61.62M
Volume · Oct 27
1.27M
Avg daily vol (3M)
639.33K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Alfred Sandrock | M.D., Ph.D. Chief Executive Officer, President, and Director | $2,508,370 |
| Jacquelyn Fahey Sandell | Former Chief Legal Officer | $1,474,986 |
| Robin Swartz | Chief Business Officer & Chief Operating Officer | $1,454,300 |
| Toby Ferguson | M.D., Ph.D. Former Chief Medical Officer | $1,364,420 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Alfred Sandrock | M.D., Ph.D. Chief Executive Officer, President, and Director | $3,379,876 |
| Toby Ferguson | M.D., Ph.D. Former Chief Medical Officer | $2,966,797 |
| Robin Swartz | Chief Business Officer & Chief Operating Officer | $1,613,804 |
| Jacquelyn Fahey Sandell | Former Chief Legal Officer | $1,232,309 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Robin Swartz | President of the Company | Appointed | 2026-10-21 |
| Amy Quinlan | principal accounting officer | Appointed | 2026-04-21 |
| Robin Swartz | principal financial officer and treasurer | Appointed | 2026-04-21 |
| Nathan Jorgensen, Ph.D. | Chief Financial Officer | Resigned | 2026-04-21 |
| Toby Ferguson, M.D., Ph.D. | Chief Medical Officer | Resigned | 2026-02-12 |
| George Scangos, Ph.D. | Class I director | Appointed | 2025-06-05 |
| Catherine J. Mackey, Ph.D. | Class I director | Appointed | 2025-06-05 |
| Glenn Pierce, M.D., Ph.D. | Class I director | Appointed | 2025-06-05 |
| Grace E. Colón, Ph.D. | Class I director | Appointed | 2025-06-05 |
| Nathan Jorgensen, Ph.D., M.B.A. | Chief Financial Officer, principal financial officer, and principal accounting officer | Appointed | 2024-06-13 |
| Robin Swartz | principal financial officer and principal accounting officer | Appointed | 2024-04-02 |
| Peter P. Pfreundschuh | Chief Financial Officer | Resigned | 2024-04-02 |
| George Scangos | director of the Company and as a member of the Science and Technology Committee of the Board | Appointed | 2023-05-09 |
| Jude Onyia, Ph.D. | director | Appointed | 2023-02-24 |
| Robert W. Hesslein | Senior Vice President and General Counsel | Resigned | 2023-02-23 |
| Grace E. Colón | director | Appointed | 2022-12-14 |
| Todd Carter, Ph.D. | Chief Scientific Officer | Appointed | 2022-09-07 |
| Todd Carter | Chief Scientific Officer | Appointed | 2022-09-07 |
| Trista Morrison | Senior Vice President of Corporate Affairs and Chief of Staff to the Chief Executive Officer | Appointed | 2022-09-07 |
| Peter P. Pfreundschuh | Chief Financial Officer | Appointed | 2022-09-07 |
| Catherine J. Mackey, Ph.D. | director | Appointed | 2022-07-28 |
Leadership
- Alfred Sandrock CEO, Board Member
- Alfred Sandrock, M.D., Ph.D. CEO, Board Member
- Michael Higgins CEO, Board Member
- Nathan Jorgensen, Ph.D., M.B.A. CFO
- Peter P. Pfreundschuh CFO
- Robin Swartz CFO, COO
- Glenn Pierce, M.D., Ph.D. CTO, Board Member
- Gregory Shiferman General Counsel
- Amy Quinlan Chief Accounting Officer
- Julie Burek Chief Accounting Officer
- Nathan Jorgensen Chief Accounting Officer
- Catherine J. Mackey Board Member
- Catherine J. Mackey, Ph.D. Board Member
- George Scangos Board Member
- George Scangos, Ph.D. Board Member
- Glenn Pierce Board Member
- Grace E. Colón Board Member
- Grace E. Colón, Ph.D. Board Member
- James A. Geraghty Board Member
- Jude Onyia Board Member
- Jude Onyia, Ph.D. Board Member
- Nancy Vitale Board Member
- Steven Hyman Board Member
Key facts
CIK
1640266
CUSIP
92915B106
13F (30d)
10 filings
10 filers
Visit website
Investor relations